ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Codex DNA Inc

Codex DNA Inc (DNAY)

1.30
0.00
(0.00%)
At close: September 20 4:00PM
1.30
0.00
( 0.00% )

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.30
Bid
1.28
Ask
1.30
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.30
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
29,984,000
Dividend Yield
-
PE Ratio
-1.90
Earnings Per Share (EPS)
-1.64
Revenue
27.51M
Net Profit
-49.02M

About Codex DNA Inc

Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specific... Codex DNA Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and reproducibly build or write high-quality synthetic DNA and mRNA that is ready to use in many downstream synthetic biology-enabled markets. It manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Show more

Sector
Lab Analytical Instruments
Industry
Lab Analytical Instruments
Headquarters
Wilmington, Delaware, USA
Founded
-

DNAY Latest News

Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with...

Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

-- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million...

Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter...

Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument

SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology...

Codex DNA Announces Plan to Change Corporate Name to Telesis Bio

SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name...

Codex DNA Expands Application of Proprietary Error Correction Technology

SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release of BioXp®...

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

SAN DIEGO, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, will showcase its recently released BioXp™ 9600 system at...

Codex DNA Debuts Next-Generation Automated Synthetic Biology Workstation

SAN DIEGO, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced commercial release and first shipment of...

Codex DNA Reports Second Quarter 2022 Financial Results

SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter...

Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JSPRWJasper Therapeutics Inc
$ 0.3333
(66.65%)
202
TGLTreasure Global Inc
$ 1.08
(58.75%)
794.45k
ULYUrgent ly Inc
$ 1.2299
(39.43%)
7.23M
NUKKNukkleus Inc
$ 0.285
(34.12%)
10.23M
NVVENuvve Holding Corporation
$ 4.50
(14.80%)
7.02k
MYNZMainz BioMed NV
$ 0.1631
(-32.88%)
1.03M
ZJYLJin Medical International Ltd
$ 2.90
(-28.92%)
205.74k
PRFXPainReform Ltd
$ 0.5599
(-27.39%)
254.01k
FRESFresh2 Group Ltd
$ 1.45
(-16.18%)
9k
CJETChijet Motor Company Inc
$ 2.35
(-16.07%)
109.65k
NVDANVIDIA Corporation
$ 116.07
(0.06%)
13.97M
NUKKNukkleus Inc
$ 0.285
(34.12%)
10.23M
MAXNMaxeon Solar Technologies Ltd
$ 0.0846
(-7.54%)
8.59M
XPONExpion360 Inc
$ 0.0754
(-11.08%)
8.57M
INTCIntel Corporation
$ 21.9697
(0.59%)
7.38M

Your Recent History